Document is current
Any future updates will be listed below
-
Authors
Cardner, Mathias https://orcid.org/0000-0001-5873-2632
Tuckwell, Danny
Kostikova, Anna
Forrer, Pascal
Siegel, Richard M
Marti, Alain
Vandemeulebroecke, Marc https://orcid.org/0000-0002-6407-3140
Ferrero, Enrico https://orcid.org/0000-0002-8362-100X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01392326 at ClinicalTrials.govnct01752634 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
FRI0451 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.2768
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct01989468 at ClinicalTrials.govDocuments that mention this clinical trial
THU0322 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year results from the phase 3 future 2 study
https://doi.org/10.1136/annrheumdis-2018-eular.2379
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
THU0311 Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 AND FUTURE 3)
https://doi.org/10.1136/annrheumdis-2018-eular.2024
OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2
https://doi.org/10.1136/annrheumdis-2017-eular.1274
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
https://doi.org/10.1016/s0140-6736(15)61134-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3
https://doi.org/10.1136/annrheumdis-2018-eular.4436
nct02294227 at ClinicalTrials.govDocuments that mention this clinical trial
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
THU0311 Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 AND FUTURE 3)
https://doi.org/10.1136/annrheumdis-2018-eular.2024
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3
https://doi.org/10.1136/annrheumdis-2018-eular.4436
nct02404350 at ClinicalTrials.govDocuments that mention this clinical trial
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
THU0373 SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.287
nct02745080 at ClinicalTrials.govDocuments that mention this clinical trial
POS1016 RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5
https://doi.org/10.1136/annrheumdis-2022-eular.278
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
https://doi.org/10.1136/rmdopen-2022-002939
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study (Results)
https://doi.org/10.1136/annrheumdis-2017-212687
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
https://doi.org/10.1136/rmdopen-2021-001600
POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5
https://doi.org/10.1136/annrheumdis-2021-eular.1862
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1971
THU0373 SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.287
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
POS0972 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OVER 2 YEARS IN FUTURE 5
https://doi.org/10.1136/annrheumdis-2024-eular.497
nct01377012 at ClinicalTrials.govDocuments that mention this clinical trial
POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1562
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
https://doi.org/10.1136/annrheumdis-2019-215386
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
POS0194 ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED
https://doi.org/10.1136/annrheumdis-2021-eular.463
FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.4736
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
https://doi.org/10.1136/annrheumdis-2020-217372
OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.4129
nct01350804 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
nct01770379 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
nct01392326 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
nct01752634 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
https://doi.org/10.1136/bmjopen-2021-058497
FRI0451 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.2768
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
nct01989468 at ClinicalTrials.govDocuments that mention this clinical trial
THU0322 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year results from the phase 3 future 2 study
https://doi.org/10.1136/annrheumdis-2018-eular.2379
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
THU0311 Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 AND FUTURE 3)
https://doi.org/10.1136/annrheumdis-2018-eular.2024
OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2
https://doi.org/10.1136/annrheumdis-2017-eular.1274
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
https://doi.org/10.1016/s0140-6736(15)61134-5
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3
https://doi.org/10.1136/annrheumdis-2018-eular.4436
nct02294227 at ClinicalTrials.govDocuments that mention this clinical trial
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
THU0311 Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 AND FUTURE 3)
https://doi.org/10.1136/annrheumdis-2018-eular.2024
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
SAT0335 Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two phase 3 studies, future 2 and future 3
https://doi.org/10.1136/annrheumdis-2018-eular.4436
nct02404350 at ClinicalTrials.govDocuments that mention this clinical trial
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
THU0373 SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.287
nct02745080 at ClinicalTrials.govDocuments that mention this clinical trial
POS1016 RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5
https://doi.org/10.1136/annrheumdis-2022-eular.278
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
https://doi.org/10.1136/rmdopen-2022-002939
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study (Results)
https://doi.org/10.1136/annrheumdis-2017-212687
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study
https://doi.org/10.1136/rmdopen-2021-001600
POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5
https://doi.org/10.1136/annrheumdis-2021-eular.1862
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2021-001845
POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1971
THU0373 SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.287
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
POS0972 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OVER 2 YEARS IN FUTURE 5
https://doi.org/10.1136/annrheumdis-2024-eular.497
nct01377012 at ClinicalTrials.govDocuments that mention this clinical trial
POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.1562
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
https://doi.org/10.1136/annrheumdis-2019-215386
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
POS0194 ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED
https://doi.org/10.1136/annrheumdis-2021-eular.463
FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.4736
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52
https://doi.org/10.1136/annrheumdis-2020-217372
OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.4129
nct01350804 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
nct01770379 at ClinicalTrials.govDocuments that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
Documents that mention this clinical trial
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003042
- License Information
